ABBV has strong fundamentals and growth, but current valuation is too high to buy; waiting for a lower price/safety margin.

The three stocks currently on my watch list are Apple, CrowdStrike, and AbbVie. But I am not buying any of them at the moment. The reason has nothing to do with her business activities. It's all about its market valuations.

This is a completely different investment situation, which leads us to the most surprising company on today's list, AbbVie, symbol ABBV. This is a name I have always loved and it is the longest center I have kept in my wallet.

This is completely different. Apple is a technology company with a huge market capitalization. CrowdStrike is a high-growth cybersecurity company. AbbVie is a major pharmaceutical company.

Typically when you think of AbbVie, you probably think of dividends, strong cash flow, defensiveness, and value.

AbbVie is a major pharmaceutical company. Typically when you think of AbbVie, you probably think of dividends, strong cash flow , defensiveness, and value.

But AbbVie's business has undergone an impressive transformation. Do you remember the great anxiety surrounding them? It was about Humira. Humira is one of the best-selling drugs in history, and investors have spent years worrying about what AbbVie will look like after Humira loses its patent exclusivity.

Well, we know the answer, and it's an answer I've talked about in many videos, Skyrizi and Rinvoq. In the last quarter, AbbVie achieved sales of $17 billion, an increase of 10%.

Its portfolio of immune-boosting products has generated nearly 9 billion. That was a 15% increase.

But look at the individual drugs, " Skyries" and "Rinvoke". "Skyrieze" generated revenues of 5.5 billion. That was an annual growth rate of 24%. Renvoc made 2.5 billion. That was a growth of approximately 25%. Meanwhile, Humira has fallen by nearly 36 %.

This is exactly what AbbVie investors wanted to see, and that's why I was urging members of my own community to buy it when it was priced below $200 per share.

But look at him now. This stock rose to $260 per share, an increase of more than 20% over the past year, excluding dividends. From the perspective of the degree of excellence, he already gets a strong score exceeding 70, reaching 75.

But what is the obstacle again? That's the evaluation. And again, as I mentioned to you, this is one of my main investments. So, when that's the case , I have the ability to be more patient with this stock.

Now, when it comes to AbbVie, it requires more precision than companies like CrowdStrike, because I would not describe AbbVie, with its current valuation, as extreme in any way as CrowdStrike. This is important.

But it operates at a different level of growth, hence the different evaluation. As you can see on your screens, the multiples have expanded over the years, something I've been talking about ever since the stock had a single-digit price-to-earnings ratio.

I have always said that AbbVie is worth a 15x multiplier, which puts it on par with many of its closest competitors.

But we are now talking about a multiple of 17.5 times from the perspective of future earnings and a multiple of 15.2 for the value of the enterprise to earnings before interest, taxes, depreciation and amortization.

Again, it's not extreme , but it's not tempting either. In fact, if you compare it to the S& P 500 index, you can say it is quite reasonable.

So why is it on today's list? Because evaluation should never be judged in isolation from others. I want to compare AbbVie's current valuation with its historical valuation, growth prospects, product pipeline, debt, dividend yield , and the return I could earn elsewhere.

The truth is, I already hold a prominent position in it. " Abfi" is a different kind of high cost of living. This is an important distinction. "Abfi" is more expensive for the return I'm looking for, and that's a much better argument.

I love the Skyrise and Renvoke properties and what they offer to the immune sector, the company’s cash flow, dividend payouts, and future production line. Management also executed the Homera transition much better than many investors feared.

But the pharmaceutical sector carries unique risks, such as patent expiration as we have seen, clinical trial failures that AbbVie faced, price pressures, and regulatory risks.

Therefore, I want to have a safety margin with every stock I buy, and at the current price, I prefer to wait for a better entry point.

When I look at these three companies, Apple, CrowdStrike and AbbVie, I love their work in its entirety, but I don't like their current ratings.

AbbVie delivers excellent performance in the pharmaceutical sector. A forward price-to-earnings ratio of 16x is not bad, but the problem lies in the lack of a safety margin after the stock's strong performance.

I love AbbVie. But I won't buy it now. Because there is a difference between wanting to own a business and being willing to pay any price for it. If the fluctuations give me the price I'm looking for, I'll be ready.

Knowing this, there are option strategies I can use to my advantage to generate more cash flow while waiting for these stocks to decline. However, tell me in the comments section which of these three stocks, if you could choose just one, you would like to own at a lower price?

Is it Apple, CrowdStrike, or AbbVie? And most importantly, what price are you expecting?